Question: As I understand, the FTO gene has been studied due to its association with obesity, and researchers are exploring its role in metabolic regulation as a potential strategy to reduce the likelihood of obesity and weight gain. Given evidence that Bisantrene is the number one agent for regulation of FTO does it not follow that Bisantrene is likely to have a future role in controlling weight gain.
I haven't seen anything mentioned or researched related to Bisantrene and weight regulation. Yes lots of qualifiers but is there a fundamental disconnection in this thought?
Future of RAC, page-27
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |